Statement re Global Blood Therapeutics, Inc.

BIOPHARMA CREDIT PLC

(THE "COMPANY")

STATEMENT RE GLOBAL BLOOD THERAPEUTICS, INC.

Pharmakon Advisors, the Investment Manager of BioPharma Credit PLC (the "Company"), notes the announcement released on Wednesday 5 October 2022 by Pfizer Inc. ("Pfizer") regarding the completion of its acquisition of Global Blood Therapeutics, Inc. ("GBT") (such acquisition, the "Transaction"). The Company had a US$132.5 million investment in a senior secured loan to GBT which was prepaid upon the closing of the Transaction. The senior secured loan was invested through three different tranches with each tranche subject to different prepayment economics. The Company received US$175.4 million in total, including US$42.9 million of accrued interest, paydown, prepayment and make-whole fees, realizing an IRR of 27.6 per cent.

Enquiries:

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

+44 (0)1392 477 500

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

+44 (0)20 7466 5000

biopharmacredit@buchanan.uk.com

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24